TEXTO : Total EXposure To Organic Pollutants

NCT02210299 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-06-10

No results posted yet for this study

Summary

People are, especially in industrialized countries, exposed to a growing number of ubiquitous chemical substances. It thus increases human exposure pathways: diet, inhalation, soil and dust dermal contact…), notably for semi-volatile organic compounds. Diet is generally sought to contribute the most to total exposure for many chemicals, the relative contribution of each pathway is nevertheless poorly described, and can be different among populations. This is in particularly the case For young children, who can be more exposed via the environment, because of frequent contact with object and dust and hand to mouth behaviors. Children are in addition considered more sensitive to chemical risk due to their maturating systems.

In this context, the objective of this project is to characterize the young children's exposure to a particular class of semi volatile organic compounds. It will encompass the relative contribution of different pathways to the external dose, and to try to match the internal and external doses with a physiologically based pharmacokinetic (PBPK) model for molecules for which it is possible.

The present demand concerns a feasibility study on 2 children, for Perfluorinated Alkylated Substances (PFAS), used in numerous consumer products.

Conditions

  • Healthy

Interventions

OTHER

Exposure study

Sampling of blood, food, water, air and dust and delivery of dietary questionnaire

Sponsors & Collaborators

  • Institut de Recherche en Santé, Environnement et le Travail, France

    collaborator OTHER
  • Laboratoire d'Etude des Résidus et Contaminants dans les Aliments

    collaborator UNKNOWN
  • Institut national de l'environnement industriel et des risques

    collaborator INDUSTRY
  • National Agency for Sanitary Safety of the Food of the Environment and Labor

    collaborator OTHER_GOV
  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Philippe Glorennec, PhD · Inserm UMR 1085 - Institut de Recherche sur la Santé, l'Environnement et le Travail

  • Florence Rouget, MD · Rennes University Hospital

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
18 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02210299 on ClinicalTrials.gov